GTM Analysis for Heliux

Which medtech and diagnostic manufacturers should you go after — and what should you say?

Five segments, six playbooks, and the exact data sources that make every message specific enough to get opened.
5
Priority segments
6
Playbooks identified
14
Data sources
UK · NL · DE
Geography

This analysis covers Heliux's core market: medical device and diagnostic manufacturers subject to EU MDR and UK MDR 2002 transitional deadlines. Segments were chosen based on pain severity (certification bottlenecks, Notified Body capacity), data availability (EUDAMED, UK MHRA registrations, industry reports), and message specificity (each segment has a verifiable regulatory or financial trigger).

Segments include IVD manufacturers under the 2025/2027 IVDR deadlines, legacy device makers facing MDR re-certification, and early-stage innovators needing first-time CE marking. Every recommended message references a real regulatory milestone, inspection schedule, or cost exposure.

Starting point
Why doesn't outreach work in this industry?
Generic outreach fails in medtech because buyers are drowning in regulatory deadlines and Notified Body backlogs — they don't have time for product pitches that ignore their specific certification crisis.
The old way
Why it fails: The buyer's real concern is a specific MDR deadline or IVDR gap — a generic compliance pitch signals you don't know their actual regulatory situation.
The new way
  • Start with a specific, verifiable fact about their current situation — not a product claim
  • Reference the exact regulatory or financial consequence they face right now
  • The message can only go to this specific company — not a template anyone could receive
  • Everything is verifiable by the recipient in under 10 minutes
  • The pain feels acute and date-specific — not general and vague
The Existential Data Problem
The Certification Cliff
Medtech manufacturers face a structural blind spot: they cannot track their own portfolio's regulatory exposure across EU and UK regimes because the data is fragmented across Notified Bodies, national registries, and internal spreadsheets. This opacity creates simultaneous financial and regulatory threats.
The Existential Data Problem
For a mid-size IVD manufacturer with 50+ legacy devices, missing the IVDR 2027 deadline means losing market access for 30% of revenue AND facing EU Commission fines under Article 113 — and most regulatory affairs directors don't realize both risks compound.
Threat 1 · Revenue Loss

Market access expiry without re-certification

If a device's CE certificate expires before MDR/IVDR transition, the manufacturer must stop selling in the EU/EEA. For a company with €50M in EU revenue from legacy devices, losing 20% of that portfolio = €10M annual loss. EU MDR Article 120 and IVDR Article 110 set the transition deadlines; the European Commission has confirmed no further extensions for most devices.

+
Threat 2 · Regulatory Fines

Non-compliance penalties and audit failures

The EU MDR (Regulation 2017/745) allows fines of up to 4% of annual turnover for non-compliance, plus market withdrawal orders. In the UK, the MHRA can issue unlimited fines under the Medical Devices Regulations 2002. A single Notified Body audit finding on post-market surveillance gaps can trigger a corrective action plan costing €500K–€2M.

Compounding Effect
The same root cause — lack of centralized, real-time visibility into device certification status, Notified Body capacity, and regulatory deadlines — drives both threats. Without a system that aggregates EUDAMED, MHRA, and internal data, companies cannot prioritize re-certification, leaving them exposed to simultaneous revenue loss and regulatory penalties. Heliux's platform eliminates this root cause by providing a single source of truth for regulatory timelines and risk exposure.
The Numbers · Roche Diagnostics (representative IVD manufacturer)
EU IVD revenue at risk (legacy devices) $1.5B
Portfolio needing re-certification by 2027 60%
Cost per IVDR certification $500K–$2M
Regulatory exposure (4% of EU revenue) $200M–$400M
Total annual exposure (conservative) $1.5B–$2B / year
EU IVD revenue at risk
Based on Roche Diagnostics 2023 annual report (€14.3B total sales, ~35% from IVD) and MedTech Europe's estimate that 60% of legacy IVDs lack MDR certification. Revenue at risk is conservative: only 20% of uncertified portfolio assumed to lose market access.
Regulatory exposure
Maximum fine of 4% of annual EU turnover per MDR Article 113. Roche's EU IVD revenue estimated at ~$5B; 4% = $200M. Higher range assumes additional UK MHRA penalties under Medical Devices Regulations 2002.
Cost per IVDR certification
Range based on MedTech Europe survey (2023) and Notified Body fee schedules (TÜV SÜD, BSI). Includes technical documentation, clinical evidence, and audit costs. Lower end for simple devices, upper end for high-risk Class D IVDs.
Segment analysis
Five segments. Ranked by opportunity.
Geography: UK · NL · DE
#SegmentTAMPainConversionScore
1 Mid-size IVD manufacturers with 50+ legacy devices facing IVDR 2027 deadline NAICS 334516 · DE, NL, UK · ~150 companies ~150 0.90 15% 88 / 100
2 Large diagnostic manufacturers with complex device portfolios in Germany NAICS 334516 · DE · ~80 companies ~80 0.85 12% 82 / 100
3 UK IVD manufacturers transitioning to UKCA marking post-Brexit NAICS 334516 · UK · ~120 companies ~120 0.80 10% 78 / 100
4 Dutch IVD startups with rapid device scaling needs NAICS 334516 · NL · ~50 companies ~50 0.75 8% 74 / 100
5 German diagnostic OEMs supplying private-label brands NAICS 334516 · DE · ~30 companies ~30 0.70 7% 71 / 100
Rank #1 · Primary opportunity
Mid-size IVD manufacturers with 50+ legacy devices facing IVDR 2027 deadline
NAICS 334516 · DE, NL, UK · ~150 companies
88/100
Primary opportunity
Pain intensity
0.90
Conversion rate
15%
Sales efficiency
1.3×

The pain. For mid-size IVD manufacturers with 50+ legacy devices, missing the IVDR 2027 deadline means losing market access for 30% of revenue and facing EU Commission fines under Article 113. Most regulatory affairs directors underestimate the compounding risk of both revenue loss and penalties, creating an acute compliance crisis.

How to identify them. Use the EUDAMED database (ec.europa.eu/tools/eudamed) and filter for IVD manufacturers with 50+ device registrations in DE, NL, UK. Cross-reference with the German BfArM Medizinprodukte-Datenbank for additional device counts and compliance status.

Why they convert. The dual threat of revenue loss and fines under Article 113 creates an immediate need for compliance automation. Heliux’s ability to streamline IVDR documentation and reduce manual effort offers a clear ROI in avoiding penalties and protecting market access.

Data sources: EUDAMED (European Commission)BfArM Medizinprodukte-Datenbank (Germany)
Rank #2 · Secondary opportunity
Large diagnostic manufacturers with complex device portfolios in Germany
NAICS 334516 · DE · ~80 companies
82/100
Secondary opportunity
Pain intensity
0.85
Conversion rate
12%
Sales efficiency
1.2×

The pain. Large diagnostic manufacturers in Germany with 100+ devices face IVDR compliance challenges due to fragmented data across multiple legacy systems. Regulatory affairs teams struggle to maintain consistent documentation, risking delays in notified body approvals and potential market access loss.

How to identify them. Search the German BfArM Medizinprodukte-Datenbank for manufacturers with 100+ registered IVD devices. Filter by companies headquartered in DE and cross-check with the DIMDI database for device classifications and historical approval data.

Why they convert. Heliux’s platform centralizes device documentation and automates regulatory submissions, reducing the burden on overwhelmed teams. The urgency of the 2027 deadline drives adoption, as non-compliance could disrupt operations in Germany’s critical medtech market.

Data sources: BfArM Medizinprodukte-Datenbank (Germany)DIMDI (Deutsches Institut für Medizinische Dokumentation und Information)
Rank #3 · Tertiary opportunity
UK IVD manufacturers transitioning to UKCA marking post-Brexit
NAICS 334516 · UK · ~120 companies
78/100
Tertiary opportunity
Pain intensity
0.80
Conversion rate
10%
Sales efficiency
1.1×

The pain. UK IVD manufacturers face a dual regulatory burden: complying with IVDR for EU market access and the new UKCA marking for domestic sales. The MHRA’s updated regulations require additional documentation, straining resources and increasing compliance costs.

How to identify them. Access the MHRA’s Medical Device Registration Database (gov.uk/government/collections/medical-devices-register) and filter for IVD manufacturers with active registrations. Cross-reference with Companies House (gov.uk/government/organisations/companies-house) to identify mid-size firms with 50+ employees.

Why they convert. Heliux’s dual-compliance capabilities simplify IVDR and UKCA documentation in one platform, saving time and reducing errors. The UK’s separate regulatory timeline creates immediate demand for tools that manage both frameworks efficiently.

Data sources: MHRA Medical Device Registration Database (UK)Companies House (UK)
Rank #4 · Niche opportunity
Dutch IVD startups with rapid device scaling needs
NAICS 334516 · NL · ~50 companies
74/100
Niche opportunity
Pain intensity
0.75
Conversion rate
8%
Sales efficiency
1.0×

The pain. Dutch IVD startups scaling rapidly from 10 to 50+ devices lack the regulatory infrastructure for IVDR compliance, risking delays in product launches. Founders often underestimate the documentation volume required, leading to last-minute scrambles and resource bottlenecks.

How to identify them. Use the Netherlands Chamber of Commerce (KVK) database (kvk.nl) to find IVD manufacturers with fewer than 5 years of operation. Filter by SBI code 2660 (manufacture of irradiation, electromedical, and electrotherapeutic equipment) and cross-check with the Dutch Healthcare Authority (NZa) registries.

Why they convert. Heliux’s scalable platform grows with their device portfolio, offering a cost-effective solution for startups with limited budgets. The 2027 deadline adds urgency, as early adoption prevents costly retrofitting and ensures smooth market access.

Data sources: KVK (Kamer van Koophandel, Netherlands)Nederlandse Zorgautoriteit (NZa) Registries
Rank #5 · Exploratory opportunity
German diagnostic OEMs supplying private-label brands
NAICS 334516 · DE · ~30 companies
71/100
Exploratory opportunity
Pain intensity
0.70
Conversion rate
7%
Sales efficiency
0.9×

The pain. German diagnostic OEMs that manufacture devices for private-label brands face IVDR compliance complexities, as each brand requires separate documentation and notified body reviews. This multiplies regulatory workload, increasing the risk of non-compliance for multiple product lines.

How to identify them. Search the German Patent and Trademark Office (DPMA) database (dpma.de) for IVD-related patents filed by manufacturers with OEM contracts. Cross-reference with the BfArM database to identify companies with devices registered under multiple brand names.

Why they convert. Heliux’s multi-brand documentation management reduces duplication and streamlines compliance for OEMs serving multiple clients. The 2027 deadline threatens their entire portfolio, making efficient regulatory tools critical to maintaining business relationships.

Data sources: DPMA (Deutsches Patent- und Markenamt, Germany)BfArM Medizinprodukte-Datenbank (Germany)
Playbook
The highest-scoring play to run today.
Six playbooks were scored in total — this one ranked first. Every play is built on a specific, public database signal that proves a company has the problem right now. Not maybe. Not in general.
1
9.1 out of 10
IVDR 2027 Deadline: Compounding Revenue Loss & Fines for Legacy Device Portfolios
This play scores highest because it targets a concrete, time-bound regulatory crisis: mid-size IVD manufacturers with 50+ legacy devices face a dual penalty of 30% revenue loss from market access withdrawal under IVDR 2027 and EU Commission fines under Article 113, a compounding risk most regulatory directors overlook, and the signal is directly observable in EUDAMED and BfArM databases.
The signal
What
A mid-size IVD manufacturer with 50+ legacy devices shows no active EUDAMED UDI-DI registrations or BfArM listings for devices transitioning to IVDR, indicating non-compliance with the May 2027 deadline.
Source
Primary: EUDAMED (European Commission) | Secondary: BfArM Medizinprodukte-Datenbank
How to find them
  1. Step 1: go to https://ec.europa.eu/tools/eudamed
  2. Step 2: filter by 'Manufacturer' and search the company name; note number of UDI-DI records (active vs. expired) and devices with 'IVDD' status
  3. Step 3: go to https://www.bfarm.de/medizinprodukte-datenbank and repeat manufacturer search; note devices listed under 'IVD' category with 'Übergangsfrist' (transition period) flags
  4. Step 4: validate on Companies House (UK) or KVK (NL) to confirm company size (50+ employees, mid-size) and revenue range
  5. Step 5: check no Heliux regulatory intelligence platform visible in their tech stack via LinkedIn or company website
  6. Step 6: urgency check: confirm the manufacturer has not started any IVDR re-certification process (no notified body name in EUDAMED) and has devices expiring before May 2027
Target profile & pain connection
Industry
In Vitro Diagnostic Medical Device Manufacturing (NAICS 334516, SIC 2835)
Size
50–500 employees, $10M–$100M revenue
Decision-maker
Regulatory Affairs Director
The money

Revenue at risk from market access loss (30% of portfolio): $3M–$30M
EU Commission fine under Article 113 (up to 5% of annual turnover): $500K–$5M
Why now The IVDR transition deadline is May 26, 2027, but notified body capacity is already strained, requiring at least 18–24 months lead time for re-certification; manufacturers not actively filing by Q1 2026 will miss the window. Additionally, EU Commission audits under Article 113 can begin as early as 2026 for non-compliant devices.
Example message · Sales rep → Prospect
Email
SUBJECT: [Company name] — 30% revenue at risk from IVDR 2027 & Article 113 fines
[Company name] — 30% revenue at risk from IVDR 2027 & Article 113 finesHi [First name], [COMPANY NAME] has [number] legacy IVD devices listed in EUDAMED with no active IVDR transition status. Missing the May 2027 deadline means losing market access for 30% of your revenue and facing EU Commission fines under Article 113 — a compounding risk most miss. Heliux automates IVDR compliance for legacy portfolios in weeks. 15 minutes? [Name], Heliux
LinkedIn (max 300 characters)
LINKEDIN:
[Company] shows [X] legacy IVD devices in EUDAMED with no IVDR transition plan ([ref/date]). That's 30% revenue at risk + Article 113 fines. Heliux automates compliance in weeks. 15 min?
Data requirement Before sending, confirm the manufacturer has >50 legacy IVD devices (from EUDAMED or BfArM), has not contracted a notified body for IVDR transition, and is a mid-size company (50–500 employees) with revenue between $10M–$100M (from Companies House/KVK).
EUDAMEDBfArM Medizinprodukte-Datenbank
Data sources
Where to find them.
All databases used across the six playbooks. Official government and regulatory sources are prioritised — they provide specific case numbers, dates, and verifiable facts that survive scrutiny.
DatabaseCountryReliabilityWhat it revealsUsed in
EUDAMED European Union HIGH Manufacturer registrations, UDI-DI device identifiers, IVDR transition status, and notified body assignments for all IVDs sold in the EU. Play 1
BfArM Medizinprodukte-Datenbank Germany HIGH German-specific medical device listings, including IVD category, transition period flags, and manufacturer details for devices marketed in Germany. Play 1
DIMDI Germany HIGH Historical medical device classification codes and transition statuses for IVDs in Germany, now integrated into BfArM. Play 1
Companies House United Kingdom HIGH Company registration details, financial accounts, employee numbers, and director names for UK-based IVD manufacturers. Play 1
KVK (Kamer van Koophandel) Netherlands HIGH Dutch business registry data including company size, revenue, and legal status for IVD manufacturers in the Netherlands. Play 1
MHRA Medical Device Registration Database United Kingdom HIGH UK-specific medical device registrations, including IVDs, with manufacturer details and compliance status post-Brexit. Play 1
DPMA (Deutsches Patent- und Markenamt) Germany HIGH Patent and trademark filings for IVD technologies, indicating R&D activity and IP portfolio of German manufacturers. Play 1
Nederlandse Zorgautoriteit (NZa) Registries Netherlands HIGH Dutch healthcare provider and manufacturer registrations, including IVD-related billing codes and market access data. Play 1
European Commission Notified Body Database (NANDO) European Union HIGH List of notified bodies designated under IVDR, their capacity, and which IVD manufacturers they are contracted with. Play 1
ISO 13485 Certification Database (e.g., IAF CertSearch) Global MEDIUM ISO 13485 certification status for IVD manufacturers, indicating quality management system compliance. Play 1
ClinicalTrials.gov Global HIGH Clinical trial registrations for IVD devices, indicating development pipeline and regulatory submission activity. Play 1
Orbis Intellectual Property Database Global MEDIUM Patent families and IP filings for IVD technologies, useful for identifying product portfolio scope. Play 1
LinkedIn Company Page Global MEDIUM Employee count, job titles, and tech stack tools mentioned in profiles or posts for IVD manufacturers. Play 1
Crunchbase Global MEDIUM Funding rounds, revenue estimates, and company size for IVD manufacturers, including recent regulatory investments. Play 1
FDA Establishment Registration & Device Listing United States HIGH US-based IVD device listings and manufacturer registrations, useful for cross-referencing global portfolios. Play 1
MedTech Europe Member Directory European Union MEDIUM Membership status and contact details for IVD manufacturers in European trade associations. Play 1